Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide and LHRH agonist with or without zoledronic acid for hormone-sensitive metastatic bone disease in prostate cancer
2017-000305-21Phase 2Completed
- Sponsor
- ASST Spedali Civili di Brescia
- Start
- Jan 2021
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of enzalutamide, zoledronic acid, leuprolide and triptorelin in prostate cancer (PCa) (2 arms), sponsored by ASST Spedali Civili di Brescia. Started Jan 2021; status: completed.
02
Drugs
enzalutamidezoledronic acidleuprolidetriptorelin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2017-000305-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000305-21.